IMMUNOCORE HOLDINGS PLC-ADR (IMCR) Stock Fundamental Analysis
USA - NASDAQ:IMCR - US45258D1054 - ADR
35 USD
+1.5 (+4.48%)
Overall IMCR gets a fundamental rating of 4 out of 10. We evaluated IMCR against 531 industry peers in the Biotechnology industry. While IMCR seems to be doing ok healthwise, there are quite some concerns on its profitability. IMCR is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year IMCR has reported negative net income.
In the past year IMCR had a positive cash flow from operations.
IMCR had negative earnings in each of the past 5 years.
In multiple years IMCR reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -1.88%, IMCR belongs to the top of the industry, outperforming 88.32% of the companies in the same industry.
The Return On Equity of IMCR (-5.23%) is better than 89.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.88% | ||
| ROE | -5.23% | ||
| ROIC | N/A |
ROA(3y)-7.93%
ROA(5y)-20.99%
ROE(3y)-14.64%
ROE(5y)-50.92%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IMCR has a Gross Margin of 99.26%. This is amongst the best in the industry. IMCR outperforms 97.93% of its industry peers.
IMCR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.26% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IMCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMCR has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, IMCR has more shares outstanding
The debt/assets ratio for IMCR is higher compared to a year ago.
2.2 Solvency
IMCR has an Altman-Z score of 1.53. This is a bad value and indicates that IMCR is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 1.53, IMCR is doing good in the industry, outperforming 65.16% of the companies in the same industry.
IMCR has a debt to FCF ratio of 13.78. This is a negative value and a sign of low solvency as IMCR would need 13.78 years to pay back of all of its debts.
The Debt to FCF ratio of IMCR (13.78) is better than 90.96% of its industry peers.
IMCR has a Debt/Equity ratio of 1.01. This is a high value indicating a heavy dependency on external financing.
IMCR has a worse Debt to Equity ratio (1.01) than 76.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.01 | ||
| Debt/FCF | 13.78 | ||
| Altman-Z | 1.53 |
ROIC/WACCN/A
WACC8.73%
2.3 Liquidity
IMCR has a Current Ratio of 5.89. This indicates that IMCR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.89, IMCR is in the better half of the industry, outperforming 62.34% of the companies in the same industry.
A Quick Ratio of 5.86 indicates that IMCR has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.86, IMCR is in the better half of the industry, outperforming 62.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.89 | ||
| Quick Ratio | 5.86 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 40.00% over the past year.
Looking at the last year, IMCR shows a very strong growth in Revenue. The Revenue has grown by 24.37%.
The Revenue has been growing by 64.57% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)24.37%
Revenue growth 3Y127.06%
Revenue growth 5Y64.57%
Sales Q2Q%29.22%
3.2 Future
Based on estimates for the next years, IMCR will show a very strong growth in Earnings Per Share. The EPS will grow by 38.95% on average per year.
IMCR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.45% yearly.
EPS Next Y28.05%
EPS Next 2Y-16.36%
EPS Next 3Y-19.6%
EPS Next 5Y38.95%
Revenue Next Year25.54%
Revenue Next 2Y16.92%
Revenue Next 3Y15.36%
Revenue Next 5Y20.45%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
IMCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
92.28% of the companies in the same industry are more expensive than IMCR, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 61.99 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IMCR's earnings are expected to decrease with -19.60% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.36%
EPS Next 3Y-19.6%
5. Dividend
5.1 Amount
No dividends for IMCR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:IMCR (11/10/2025, 8:00:02 PM)
35
+1.5 (+4.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.45%
Inst Owner Change-0.12%
Ins Owners0.03%
Ins Owner Change0%
Market Cap1.76B
Revenue(TTM)310.20M
Net Income(TTM)-20.31M
Analysts81.6
Price Target67.19 (91.97%)
Short Float %17.58%
Short Ratio27.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)62.74%
Min EPS beat(2)0.3%
Max EPS beat(2)125.17%
EPS beat(4)3
Avg EPS beat(4)48.38%
Min EPS beat(4)-79.43%
Max EPS beat(4)147.46%
EPS beat(8)5
Avg EPS beat(8)35.65%
EPS beat(12)7
Avg EPS beat(12)-206113%
EPS beat(16)9
Avg EPS beat(16)-154577%
Revenue beat(2)2
Avg Revenue beat(2)2.92%
Min Revenue beat(2)1.34%
Max Revenue beat(2)4.49%
Revenue beat(4)2
Avg Revenue beat(4)-0.15%
Min Revenue beat(4)-4.08%
Max Revenue beat(4)4.49%
Revenue beat(8)4
Avg Revenue beat(8)-0.07%
Revenue beat(12)7
Avg Revenue beat(12)3.9%
Revenue beat(16)11
Avg Revenue beat(16)25.29%
PT rev (1m)3.14%
PT rev (3m)9.66%
EPS NQ rev (1m)5.6%
EPS NQ rev (3m)-6.42%
EPS NY rev (1m)3.84%
EPS NY rev (3m)10.51%
Revenue NQ rev (1m)-3.06%
Revenue NQ rev (3m)1.79%
Revenue NY rev (1m)0.31%
Revenue NY rev (3m)2.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.95 | ||
| P/FCF | 61.99 | ||
| P/OCF | 52.53 | ||
| P/B | 4.54 | ||
| P/tB | 4.54 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.57
EYN/A
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)0.56
FCFY1.61%
OCF(TTM)0.67
OCFY1.9%
SpS7.07
BVpS7.71
TBVpS7.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.88% | ||
| ROE | -5.23% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.26% | ||
| FCFM | 7.99% |
ROA(3y)-7.93%
ROA(5y)-20.99%
ROE(3y)-14.64%
ROE(5y)-50.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.01 | ||
| Debt/FCF | 13.78 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 133.61% | ||
| Cap/Sales | 1.44% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.89 | ||
| Quick Ratio | 5.86 | ||
| Altman-Z | 1.53 |
F-Score5
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)97.19%
Cap/Depr(5y)68.03%
Cap/Sales(3y)1.79%
Cap/Sales(5y)3.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y28.05%
EPS Next 2Y-16.36%
EPS Next 3Y-19.6%
EPS Next 5Y38.95%
Revenue 1Y (TTM)24.37%
Revenue growth 3Y127.06%
Revenue growth 5Y64.57%
Sales Q2Q%29.22%
Revenue Next Year25.54%
Revenue Next 2Y16.92%
Revenue Next 3Y15.36%
Revenue Next 5Y20.45%
EBIT growth 1Y54.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.31%
EBIT Next 3Y-21.4%
EBIT Next 5Y35.12%
FCF growth 1Y82.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.54%
OCF growth 3YN/A
OCF growth 5YN/A
IMMUNOCORE HOLDINGS PLC-ADR / IMCR FAQ
What is the ChartMill fundamental rating of IMMUNOCORE HOLDINGS PLC-ADR (IMCR) stock?
ChartMill assigns a fundamental rating of 4 / 10 to IMCR.
Can you provide the valuation status for IMMUNOCORE HOLDINGS PLC-ADR?
ChartMill assigns a valuation rating of 2 / 10 to IMMUNOCORE HOLDINGS PLC-ADR (IMCR). This can be considered as Overvalued.
How profitable is IMMUNOCORE HOLDINGS PLC-ADR (IMCR) stock?
IMMUNOCORE HOLDINGS PLC-ADR (IMCR) has a profitability rating of 3 / 10.
What is the earnings growth outlook for IMMUNOCORE HOLDINGS PLC-ADR?
The Earnings per Share (EPS) of IMMUNOCORE HOLDINGS PLC-ADR (IMCR) is expected to grow by 28.05% in the next year.